Supporting the Dementias Research Platform UK

RNS Number : 6444V

Cambridge Cognition Holdings PLC

30 October 2014

 



Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

Supporting the Dementias Research Platform UK

Cambridge Cognition, (AIM: COG), which specialises in computerised neuropsychological tests, announces that the Company strongly supports the launch of The Medical Research Council ('MRC') Dementias Research Platform UK ('DPUK'). Cambridge Cognition's Cantab Connect is playing a significant role in the ongoing DPUK Dementia Deep and Frequent Phenotyping feasibility study.

This joint-funded National Institute for Health Research ('NIHR') and MRC project for intensive phenotyping of 24 pre-clinical Alzheimer's disease patients, aims to identify biomarkers that change over periods of months, rather than years. The Deep and Frequent Phenotyping study assesses key cognitive domains affected in Alzheimer's disease using Cambridge Cognition's rapid touchscreen cognitive test system, Cantab Connect.

Alongside the cognitive tests, the study uses an extensive range of MR imaging, additional clinical testing and biomarkers, at frequent intervals during the three months study period for each participant. The goal is to identify protocols and biomarkers that will be used in a wide range of follow-on trials

The MRC DPUK is a £53m public-private partnership with World leading researchers from Universities across the UK (Cambridge, Cardiff, Edinburgh, Imperial College, Oxford, Manchester, Newcastle, Swansea and UCL) and six companies (GlaxoSmithKline, Janssen Research & Development, AstraZeneca-MedImmune, Ixico, SomaLogic and Araclon) who will use state of the art technologies such as Cantab Connect to accelerate progress in dementias research. It brings together two million participants aged 50 and over, from 22 existing study groups within the UK, making it the World's largest population study for use in dementias research. The DPUK's aims are early detection, improved treatment and ultimately, prevention, of dementias.

Dr Jenny Barnett, Director of Healthcare Innovation at Cambridge Cognition commented: "We fully support the DPUK initiative and are pleased to see the UK setting a leading example to accelerate early detection of dementia and develop knowledge leading to new diagnostic procedures, drug treatments and other therapies that could prevent or delay the onset and progression of Alzheimer's and other neurodegenerative diseases."

Chief Executive Officer of Cambridge Cognition, Nick Kerton, commented: "This represents the largest population-based study on the progress of dementia.  It is a testament to the quality and utility of the products that we have developed that they will be used as an integral part of this study."

Cambridge Cognition Holdings plc	www.cambridgecognition.com
Nick Kerton, Chief Executive Officer	Tel: [phone]
Nick Walters, Chief Financial Officer
finnCap Ltd (Nomad and Broker)	Tel: [phone]
Matthew Robinson/Henrik Persson/Simon Hicks	(Corporate Finance)
Malar Velaigam	(Corporate Broking)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus	Mob: [phone]
Lianne Cawthorne	Mob: [phone]

 

END

 

 

NRALLFSRIRLAFIS